Eloxx Pharmaceuticals doses first patients in Phase 2B Exaluren study
Eloxx Pharmaceuticals says it has dosed first patients in its Phase 2B Exact study of exaluren for nonsense mutation Alport syndrome.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.